Zur Hauptnavigation wechseln Zur Suche wechseln Zum Hauptinhalt wechseln

Oxazepam alters action monitoring

Sönke Johannes*, Bernardina M. Wieringa, Wido Nager, Reinhard Dengler, Thomas F. Münte

*Korrespondierende/r Autor/-in für diese Arbeit

Abstract

Rationale: Oxazepam has been demonstrated to slow reaction times and increase the rate of omission errors in attentional experiments. This suggests that action monitoring might also be impaired. Objectives: The present study used the event-related brain potential (ERP) technique to investigate this hypothesis. The P3b component to targets was taken as an indicator of the target evaluation process, and the response-locked error-related negativity (ERN) served as an indicator of action monitoring. We hypothesized that the amplitudes of ERN and P3b would be reduced as an effect of oxazepam. Methods: A simple "oddball" reaction time experiment was conducted in a double-blind crossover study of 30 mg oxazepam versus placebo. In order to investigate variations in attentional allocation, separate experimental runs were undertaken with target frequencies of 50% and 80%. Results: ERN and P3b amplitudes were lower in the 80% target condition than in the 50% condition. Oxazepam did not affect behavioral parameters but was associated with an ERN of lower amplitude than the placebo condition. ERN amplitude variations between target conditions remained unchanged. Conclusions: Although the intake of 30 mg oxazepam did not impair behavioral performance, measures of the electrophysiological recordings show that action monitoring processes were altered. We argue that this may be related to the anxiolytic properties of the drug and may constitute an important causal factor for behavioral impairments after the intake of oxazepam.

OriginalspracheEnglisch
ZeitschriftPsychopharmacology
Jahrgang155
Ausgabenummer1
Seiten (von - bis)100-106
Seitenumfang7
ISSN0033-3158
DOIs
PublikationsstatusVeröffentlicht - 01.01.2001

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

  1. SDG 3 – Gesundheit und Wohlergehen
    SDG 3 – Gesundheit und Wohlergehen
  2. SDG 10 – Weniger Ungleichheiten
    SDG 10 – Weniger Ungleichheiten

Strategische Forschungsbereiche und Zentren

  • Forschungsschwerpunkt: Gehirn, Hormone, Verhalten - Center for Brain, Behavior and Metabolism (CBBM)

Fingerprint

Untersuchen Sie die Forschungsthemen von „Oxazepam alters action monitoring“. Zusammen bilden sie einen einzigartigen Fingerprint.

Zitieren